1189P - Impact of Adenocarcinoma Versus Squamous-Cell-Carcinoma Histology on Survival of Resected Stage I-II Non-Small Cell Lung Cancer (NSCLC) in a Cohort of 509 Patients

Abstract

ABSTRACT Background Histology is a prognostic and predictor of the response factor in advanced non-small cell lung cancer (NSCLC). Adenocarcinoma (ADC) has a better prognosis in advanced NSCLC whereas it is considered that resected patients (pts) with squamous-cell-carcinoma (SqCC) have a better outcome. We have analyzed our experience of resected stage I-II NSCLC pts to determine the impact of ADC vs SqCC histology in this setting. Methods From 1996 to 2010, 289 stage I pts and 220 stage II pts were treated by surgery. Chemotherapy (CT) was administered in 19 (6.6%) pts with stage I disease and 94 (42.7%) pts with stage II disease. Overall survival (OS) and cause-specific survival (CSS) curves were estimated by Kaplan-Meier analysis and differences were assessed with the log-rank test or the Peto and Peto modification of the Gehan-Wilcoxon test. Results Most pts (92.9%) were men. Median age was 68 years and mean follow-up was 37.4 months. Median OS for pts with stage I NSCLC was 68 mo (IC 95: 55-123) for ADC and 55 mo (IC 95: 47-67) for SqCC (p = 0.0604) with an estimated OS at 5 years of 54.1% vs 48%. Median CSS were not achieved in the two histology groups, with an estimated CSS at 5 years of 78.3% for ADC versus 71.5% for SqCC (p = 0. 626). For pts in stage II disease, the median OS was 31 mo (IC 95: 21-45) for ADC and 24 mo (IC 95: 18-34) for SqCC (p = 0.515) with an estimated OS at 5 years of 20.5% vs 29.6%. Median CSS were 45 mo (IC 95: 31-NA) for ADC and 93 mo (IC 95: 39-NA) for SqCC (p = 0.462), with an estimated CSS at 5 years of 44.8% vs 54.3%. Conclusions A trend for better OS of ADC was observed in stage I compared to SqCC but it disappeared for CSS. Thus, no statistically significant differences in OS nor CSS were observed in resected stage I-II NSCLC patients between ADC vs SqCC histology. Disclosure All authors have declared no conflicts of interest.